Lilly's Diabetic Neuropathy Agent Ruboxistaurin Will Be Called Arxxant
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly is proposing to market the diabetic peripheral neuropathy agent ruboxistaurin under the trade name Arxxant